Protagenic Therapeutics (PTIX) and Phytanix Bio said Monday that they have agreed to combine in an all-stock deal.
Shares almost quadrupled as intraday trading volume catapulted to over 80 million from a daily average of about 460,000.
BrainStorm Cell Therapeutics (BCLI) said it has received clearance from the US Food and Drug Administration to launch a phase 3b trial of NurOwn to treat amyotrophic lateral sclerosis.
Shares jumped 18%, with intraday trading volume at over 54 million versus a daily average of roughly 178,000.
Roth Capital raised its price target on Sable Offshore (SOC) to $38 from $26 while maintaining its buy rating.
Shares rose 20% as trading volume surged to more than 5.8 million from a daily average of about 1.6 million.
Price: 11.85, Change: +8.82, Percent Change: +291.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.